or Try an Advanced Search...

    Technical Analysis for DYN - Dyne Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 15.00 -1.90% -0.29
    DYN closed down 1.9 percent on Tuesday, January 14, 2025, on 1.87 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical DYN trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Calm After Storm Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Older End-of-Day Signals for DYN ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 8 hours ago
    Down 2 % about 10 hours ago
    60 Minute Opening Range Breakdown about 10 hours ago
    Down 1% about 11 hours ago
    Rose Above Previous Day's High about 11 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    DYN Chart by TradingView

    Profile

    Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Oligonucleotide Duchenne Genetic Genealogy Myotonic Dystrophy Dystrophin Facioscapulohumeral Muscular Dystrophy Muscle Disease Muscle Diseases

    Is DYN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 10 Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall
    Jan 10 Dyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatment
    Jan 10 Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE...
    Jan 9 Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
    Jan 8 Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
    Dec 13 Dyne Therapeutics initiated with Outperform at Baird
    Nov 26 Dyne, Avidity initiated at outperform by RBC on DM1 drugs
    Nov 22 Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
    Nov 12 Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25
    Nov 12 Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    See more DYN news...

    Comments

    Indicators

    Indicator Value
    52 Week High 47.45
    52 Week Low 14.7923
    Average Volume 1,243,390
    200-Day Moving Average 32.33
    50-Day Moving Average 26.76
    20-Day Moving Average 23.10
    10-Day Moving Average 21.51
    Average True Range 1.84
    RSI (14) 18.70
    ADX 27.81
    +DI 10.48
    -DI 40.03
    Chandelier Exit (Long, 3 ATRs) 23.44
    Chandelier Exit (Short, 3 ATRs) 20.31
    Upper Bollinger Bands 29.79
    Lower Bollinger Band 16.41
    Percent B (%b) -0.11
    BandWidth 57.92
    MACD Line -2.70
    MACD Signal Line -1.83
    MACD Histogram -0.8669
    Fundamentals Value
    Market Cap 1.22 Billion
    Num Shares 81.1 Million
    EPS -3.59
    Price-to-Earnings (P/E) Ratio -4.18
    Price-to-Sales 0.00
    Price-to-Book 12.82
    PEG Ratio 0.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 16.55
    Resistance 3 (R3) 16.67 16.29 16.29
    Resistance 2 (R2) 16.29 15.89 16.22 16.20
    Resistance 1 (R1) 15.64 15.65 15.45 15.52 16.12
    Pivot Point 15.26 15.26 15.16 15.19 15.26
    Support 1 (S1) 14.61 14.86 14.42 14.49 13.88
    Support 2 (S2) 14.23 14.62 14.16 13.80
    Support 3 (S3) 13.58 14.23 13.71
    Support 4 (S4) 13.46